Session 3: From molecular addiction to therapeutic strategy in NSCLC - Panel discussion Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019
Session 1: From molecular alterations to cancer immunity in NSCLC - Panel discussion Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019
Session 2: From molecular target to molecular resistance in NSCLC - Panel discussion Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019
Afatinib (A) vs gefitinib (G) as first-line treatment (tx) for patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: LUX-Lung 7 Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016
LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) vs gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung Source: Annual Congress 2013 –Advances in the therapy of lung cancer Year: 2013
Long term results of the randomized phase 2 trial on refinement of early stage NSCLC adjuvant chemotherapy with cisplatin/pemetrexed (CPx) versus cisplatin/vinorelbine (CVb) - TREAT Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours Year: 2014
Anticancer chemotherapy combined with anti-tuberculosis treatment: A systematic review Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013
TTF 1- expression and pemetrexed based chemotherapy. A retrospective analysis Source: International Congress 2015 – Diagnosis and therapy of lung cancer Year: 2015
Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung: LUX-Lung 8 (LL8), a phase III trial Source: International Congress 2015 – Advances in the therapy of lung cancer Year: 2015
Safety analysis of anti-VEGF therapy bevacizumab (Bv) in patients (pts) with untreated advanced non-small cell lung cancer (NSCLC) in MO19390 (SAiL) trial Source: Annual Congress 2008 - Therapy in thoracic oncology Year: 2008
Efficacy and safety of full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer (NSCLC) patients: Results of a prospective study in nonrandomized population of 259 patients Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013
A phase III trial comparing concomitant radiochemotherapy (RT-CT) with cisplatin (P) and docetaxel (D) as induction versus consolidation in patients with locally advanced unresectable non-small cell lung cancer (NSCLC). An ELCWP study Source: International Congress 2015 – Advances in the therapy of lung cancer Year: 2015
Late Breaking Abstract - Analysis of the InforMing the PAthway of COPD Treatment (IMPACT) study in the subgroup of patients taking triple therapy at screening Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS Year: 2018
Survival in 138 patients with non small cell lung cancer (NSCLC) treated with platinum together with gemcitabine or vinorelbine by a multidisciplinary team. Comparison with the Big Lung Trial Source: Eur Respir J 2006; 28: Suppl. 50, 781s Year: 2006
Late Breaking Abstract - Randomized phase III study of erlotinib compared to intercalated erlotinib with cisplatin and pemetrexed as first-line therapy for advanced EGFR mutated non-small cell lung cancer, the NVALT 17 study. Source: Virtual Congress 2021 – New clinical and biological developments in lung cancer Year: 2021
Analysis of overall survival (OS) in two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut) Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours Year: 2014
Gefitinib as first-line treatment for patients with NSCLC with activating EGFR mutationin exons 19 (Del19) or 21 (L858R) in the Czech Republic Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015
Pulmonary function during lung cancer therapy: A retrospective analysis of patients treated with monotherapy or multimodal treatments Source: International Congress 2016 – Clinical aspects of lung cancer Year: 2016
Panel discussion: Improving the pathway of lung cancer patients, can we do it better? Source: ERS webinar 2021: Panel discussion on improving the pathway of lung cancer patients, can we do it better? Year: 2021